key: cord-0692560-oghziwn8
authors: Alsharidah, Sondas; Ayed, Mariam; Ameen, Reem M.; Alhuraish, Fatma; Rouheldeen, Najat A.; Alshammari, Farah R.; Embaireeg, Alia; Almelahi, Mariam; Adel, Maitham; Dawoud, Mohammed E.; Aljasmi, Mohammad A.; Alshammari, Nashmi; Alsaeedi, Abdullah; Al-Adsani, Wasel; Arian, Hussan; Awad, Husain; Alenezi, Humoud A.; Alzafiri, Azeez; Gouda, Enas F.; Almehanna, Mohammad; Alqahtani, Salem; Alshammari, Abdulrahman; Askar, Medhat Z.
title: COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study
date: 2020-12-04
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.11.198
sha: a15bb937f7ea641f9d3b4954f76269c84a6580dd
doc_id: 692560
cord_uid: oghziwn8

Objective To study the effectiveness of CCP therapy for moderate and severe COVID-19 disease patients in Kuwait. Methods This non-randomized prospective cohort study was conducted from May 21, 2020, to June 30, 2020, at four major tertiary hospitals in Kuwait. CCP was administered to 135 patients. The control group comprised 233 patients who received standard treatment. All patients (N = 368, median age 54 [range 15-82] years) had laboratory-confirmed SARS-CoV-2 infection and either moderate or severe COVID-19 disease. Results CCP treatment was significantly associated with a higher rate of clinical improvement in patients with moderate or severe disease. Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CCP group versus 8 days in the control group (p = 0·006). For severe COVID-19 disease, time to clinical improvement was 7 days in the CCP group versus 15.5 days in the control group (p = 0·003). In the adjusted analysis, the CCP-treated patients with moderate disease had significantly lower 30-day mortality. Compared to the control group, oxygen saturation improved within 3 days of CCP transfusion, and lymphocyte counts improved from day 7 in patients with moderate disease and day 11 in patients with severe disease. Furthermore, C-reactive protein declined throughout the first 14 days after CCP transfusion. None of the CCP patients developed a serious transfusion reaction. Conclusions The data show that administration of CCP is a safe treatment option for patients with COVID-19 disease, with a favorable outcome in the rate and time to clinical improvement.

The novel coronavirus disease of 2019 pandemic is considered one of the greatest global public health crises since the 1918 influenza pandemic. 1 COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a singlestranded RNA virus that belongs to coronaviridae. 2, 3 The clinical spectrum of infection is broad, ranging from asymptomatic to severe pneumonia, multiorgan failure, and death.

Due to the absence of established antiviral treatment for COVID-19, the historical choice of therapeutic convalescent plasma (CP) was globally appealing, especially with its prior success against RNA viruses. 1 CP has been proposed not only to neutralize the pathogen, but provide passive immunomodulatory properties that allow the recipient to control the J o u r n a l P r e -p r o o f exaggerated inflammatory cascade. 4, 5 However, the mechanism of action of therapeutic CP remains unclear. Reports from open label trials and case series suggest that plasma collected from convalescent COVID-19 patients is safe to administer and may be effective in treating patients with COVID-19. [6] [7] [8] Therefore, the World Health Organization (WHO) and

United States Food and Drug Administration (FDA) have issued guidelines for the usage of COVID-19 convalescent plasma (CCP) and standardized donor selection, which was further supported by an Emergency Use Authorization (EUA) from the FDA. 9, 10 A number of reports have demonstrated promising results of CCP in severe and critically ill COVID-19 patients, albeit not consistently. 8, [11] [12] The effectiveness of CCP in less than severe cases remains unclear. The aim of the current study was to assess the effectiveness of CCP in both moderate and severe COVID-19 cases compared to the standard treatment alone. The CCP effectiveness was evaluated in terms of time to clinical improvement and hospital mortality, the changes in oxygen saturation and laboratory markers (lymphocytes, neutrophils counts, lactate dehydrogenase [LDH] , and C-reactive protein [CRP] ).

This prospective multicenter interventional study was conducted in four major tertiary hospitals in Kuwait (Al-Sabah, Farwaniya, Mubarak Al-Kabeer, and Jahra) from May 21 to June 30, 2020, with the last follow-up data collected July 12, 2020. All patients and CCP donors had confirmed SARS-CoV-2 infection by an EUA-approved real-time reverse transcriptase-polymerase chain reaction (RT-PCR) using nasopharyngeal swabs (Cobas 6800 Systems, Roche, Switzerland and Taq Path, Thermo-Fisher Scientific, USA). The CCP donors were tested for SARS-CoV-2 IgG using a CE-marked rapid test (BIOZEK COVID-19

IgG/IgM qualitative test: Inzek International Trading, Apeldoom, the Netherlands ).

The study protocol was approved by the Ethics and Research Committee of Kuwait Ministry of Health (#2020/1417). Written informed consent was obtained from all patients or next of J o u r n a l P r e -p r o o f kin. If the patient was unconscious and next of kin not available, the healthcare proxy provided written informed consent.

We included patients aged ≥18 years with confirmed laboratory diagnosis of SARS-CoV-2 infection and admission diagnosis of COVID-19. Patients <18 years old were enrolled after thorough evaluation and discussion among an interdisciplinary team. Patients were eligible for CCP if they had moderate or severe COVID-19 as determined according to the WHO classification at admission by the treating physician. 9 Patients with moderate disease exhibited clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) and had SpO2 >90% in room air. Patients with severe disease exhibited clinical signs of pneumonia and at least one of the following: respiratory rate >30 breaths/minutes, SpO2<90% in room air, or admission to intensive care unit (ICU) for respiratory support (i.e., non -invasive mechanical ventilation and intubation).

Patients were excluded if they had a contraindication to transfusion (volume overload, history of anaphylaxis to blood products), acute severe multiorgan failure, hemodynamic instability, severe disseminated intravascular coagulopathy (DIC), septic shock, or expected survival of less than 48 hours.

After screening for the inclusion and exclusion criteria, we applied a systematic stratified sampling technique to identify control patients from the COVID-19 national registry. For J o u r n a l P r e -p r o o f each patient who received CCP, we selected the first two patients with the same disease severity strata admitted on that calendar date from the same participating center.

Standard treatment was based on our institutional protocol and international guidelines. 13 The majority of patients received antibiotics and low molecular weight heparin. None of our patients received antiviral therapy or hydroxychloroquine. Special therapy (i.e., steroids and/or tocilizumab) was prescribed at the discretion of treating physicians.

Clinical and laboratory data were extracted from patient medical records using a standardized data collection sheet. We captured pre-existing medical conditions, including diabetes mellitus, hypertension, and obesity. Specific therapies, such as anticoagulants, antibiotics, steroids, and tocilizumab, was also collected. Complete blood counts (CBCs), CRP, D-dimer, and LDH were also collected on days 1, 3, 7, 11, and 14 of hospitalization.

We followed the patients' progress daily from day 1 through day 30 or until discharge, whichever came first. Clinical improvement was defined as a two-grade decrease from hospitalization by assessing the clinical status based on the WHO ordinal scale. 9

The CP was collected from individuals who had recovered from RT -PCR-confirmed COVID- 

Categorical variables are presented as number and percentage (% A Cox proportional hazards model was used to assess the overall 30-day clinical improvement. Hazard ratios (HRs) with 95% CIs were reported in the Cox model. For the J o u r n a l P r e -p r o o f secondary endpoint, we calculated the OR and 95% CI using logistic regression analysis.

Variables included in the multivariate Cox proportional hazard and logistic regression models were age, baseline SpO2 < 88%, lymphocyte count <1 x10 9 , and CRP.

We also examined whether an interaction occurred between CCP and adjunct therapy (i.e., steroids and/or tocilizumab) that affected the outcomes. We tracked laboratory results, including lymphocyte and neutrophil counts, CRP, D-dimer, and LDH, in addition to oxygen saturation over time. For the analysis of repeated measures, we used a linear fixed model (regression coefficient β with 95% CI) to analyze the effect of CCP on laboratory markers and oxygen saturation at baseline and during the first 14 days of hospitalization .

Missing data were not handled in a specific manner. Statistical analyses were carried out using Stata 14 software (StataCorp, College Station, Texas). Two-sided p-values <0·05 were considered significant.

A total of 368 patients were included in the cohort; 135 received CCP and 233 were in the control group ( Figure 1 ). Demographic and baseline characteristics are shown in Table 1 .

The median age was 54 (range 15-82) years, and the majority of patients were male (n=304, 82·6%). We found no differences among groups in the baseline characteristics or admission laboratory values, with the exception of baseline CRP, which was significantly higher in the CCP-treated patients with severe disease than other groups.

Overall 30-day clinical improvement was observed in 77 (86·5%) of the CCP-treated patients with moderate disease and 106 (68·4%) of corresponding controls (p=0·001). Among those with severe disease, clinical improvement was observed in 28 (60 ·8%) of the CCP-treated patients and 27 (34·6%) of their control counterparts (p=0·001). The median time to clinical improvement among those with moderate disease was 7 (IQR 4-9) days with CCP treatment and 8 (IQR 6-12) days in the control group (p=0·006), and among those with severe disease J o u r n a l P r e -p r o o f was 7 (IQR 5-12) days with CCP treatment and 15.5 (IQR 10-20) days in the control group (p=0·003, Figure 2 (Table 2 ). There was no significant interaction effects between CCP and steroids (p=0·40), tocilizumab (p=0·12), or steroids plus tocilizumab (p=0·44) on the clinical improvement.

In univariate analysis, the CCP-treated patients in both severity groups had lower mortality rates than the control groups (n=10, 11·4% and n=14, 30·4% versus n=46, 29·7% and n=44, 57·1%; p=0·001 and p=0·006, respectively). In the adjusted model, the risk of mortality was significantly lower in the CCP-treated patients with moderate disease (adjusted OR, 0·27

[95% CI 0·12-0·62]) compared to the control group, but not significantly different in the CCPtreated patients with severe disease (adjusted OR, 0·38 [95% CI 0·14-1·02]) compared to the control group. no significant interaction effects between CCP and steroids ( p=0·36 for interaction), CCP and tocilizumab (p=0·56 for interaction), or CCP and steroids plus tocilizumab (p=0·75 for interaction) on mortality.

The effects of CCP on patients' oxygen saturation and laboratory markers over the first 14 days of the hospital stay are shown in Table 3 

Currently, no vaccine or specific antiviral treatments are approved for COVID-19 patients.

CP is a widely available non-pharmaceutical treatment that has been used with varying degrees of success in prior pandemics, including SARS, MERS, and Ebola . [15] [16] [17] [18] In our study, after CCP treatment. 7 However, the study was terminated early after enrollment of 52 patients who received CCP and 51 in the control group and may have been underpowered to detect significant differences. In contrast, our study included 135 patients in the CCP arm and 233 controls. Another report, concluded that CCP treatment did not reduce mortality and suggested that earlier adminstration of CCP might be beneficial. 12 The fact that patients in our study received CCP within 24 hours of hospital admission may have contributed to improving outcomes. In our study, CCP administration was associated with both a higher rate of and faster time to clinical improvement among patients with moderate and severe disease. The clinical improvement was observed in 80·6% of the CCP group compared to 58·6% of the control group. In addition, median time to clinical improvement in the CCP group was 7 days compared to 10 days in the control group. This is consistent with a prior case series of 10 patients, in which symptoms resolved within the first 72 hours with complete improvement on radiological examination within 7 days post-CCP administration. 19 In the H1N1 pandemic, CP was associated with a significant reduction in mortality, especially if administered early. 20 An exploratory post hoc meta-analysis revealed a significant reduction in the pooled odds of mortality following CP treatment of SARS coronavirus infection and severe influenza compared to placebo or no therap y. 21 Li et al. did not detect a significant reduction in 28-day mortality among CCP-treated patients. 7 In our study, 30-day mortality was significantly reduced in moderate, but not severe, COVID-19

cases. This may imply that CCP is more effective in reducing 30-day mortality in moderate disease, or may be attributed to inclusion of a relatively small number of severe cases. Our results are also consistent with those of a single arm study of 46 patients with moderate to severe disease where 7-day mortality was 6.5% in patients who received CCP compared to the 15% average national statistics and 30% in a concurrent cohort of 23 patients. 22 J o u r n a l P r e -p r o o f CCP in our study was also associated with significantly improved oxygen saturation and recovery in lymphocyte counts and CRP within 14 days post-CCP treatment. These findings are consistent with recent reports of the effect of CCP. 8, 11, 23 Prior studies have associated lower lymphocyte counts and high CRP levels with adverse outcomes in COVID-19 patients. 1, 19 In our study, lymphocyte counts started to increase 1 day after CCP transfusion, with a significant increase 7 days post-admission in the CCP group compared to the control group. Furthermore, CRP was remarkably decreased starting day 1 in the CCP group. The improvement of both lymphocyte counts and CRP in our study may be attributed in part to a previously postulated immunomodulatory effect of CCP such as providing passive immunity by blocking inflammatory cytokines, autoantibodies, and complement pathways. 24 CCP may also inhibit inflammatory cascades and immune cell infiltration within the lungs. 25 These effects can clinically be seen as improvement in oxygen saturation and pulmonary radiological lesions. 19 In our study, oxygen saturation significantly increased in CCP-treated patients during the first 72 hours. This finding is consistent with earlier studies reporting associations between CCP and improved oxygen saturation. 8, 23 All CCP recipients tolerated the transfusion except for 3 (2%) who had minor allergic skin reactions, which resolved completely without preventing administration of the full CCP dose.

A recent study of early safety indicators for CCP reported 36 cases (0 ·72%) with serious adverse effects (SAEs). 26 The incidence of severe allergic reaction in that study was 0·06%, and the incidence of less than severe allergic reactions was not reported.

Our study has a number of limitations, including a lack of randomization. However, randomization was not feasible during the pandemic in our region. The administration of CCP within 24 hours of hospital admission was intended to limit selection bias. Another limitation is that at the time of analysis some patients were still hospitalized which may have biased the results. The clinical management of a potentially life-threatening illness with an unpredictable clinical course was the main contributor to this limitation. In addition, there was not an approved standard protocol for the treatment during our study, especially regarding J o u r n a l P r e -p r o o f steroid and tocilizumab use. However, this stems from the lack of universally established treatments for COVID-19. We did not observe an interaction between the administration of either/both of the drugs and the observed effect of CCP in our patients. Finally, we were not able to determine the titer of SARS-CoV-2 IgG antibodies in CCP donors or whether the detected antibodies were neutralizing antibodies due to a lack of these tests in Kuwait at the time of the study. We did exclude any donors who were negative for IgG antibodies. Not performing additional antibody characterizing tests could only lead to underestimation of the benefit of this therapeutic modality due to potential inclusion of CCP units with low IgG levels or antibodies of limited neutralizing capacity. In addition, in many parts of the world, including some developed countries, there is a striking shortage of testing for COVID-19 in general, and particularly for more specialized tests, such as neutralizing antibodies.

To the best of our knowledge, this study is the first to investigate the effectiveness and feasibility of CCP in COVID-19 patients in the Middle East. Although we did not perform an a priori sample size calculation, 135 patients in the CCP group demonstrated significant differences. The involvement of multiple centers supports the generalizability of the results.

Throughout the worldwide lockdown, the supply of CCP was consistently available in Kuwait, which offers free access to this therapeutic intervention. This contrasts pharmaceuticals subject to supply chain limitations. Availability is crucial in the Middle East, which relies on pharmaceutical manufacturing that is currently concentrated in Western countries.

In our prospective interventional study including patients with mode rate and severe COVID-19, CCP administration was significantly associated with improved clinical outcome s. Thirtyday survival was significantly improved in the moderate group. In addition, administration of CCP in both moderate and severe cases was also associated with improved oxygen saturation and recovery of lymphocytes and CRP. Larger multicenter controlled randomized trials to further evaluate the effectiveness of CCP in COVID-19 patients with particular emphasis on CCP donor qualification based on neutralizing antibody levels are warranted. Trial registration: Clinicaltrials.gov NCT04474340.

We declare no competing interests. *Adjusted for age, baseline oxygen saturation < 88%, lymphocytes <1x10 9 , and C-reactive protein All values are compared to laboratory values at baseline (before CCP or at admission in control group), CCP compared to control NA=not available Values are expressed as β coefficient (95% CI) *p-value<0·05 **p-value<0·001

Treatment for emerging viruses: Convalescent plasma and COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

A Novel Coronavirus from Patients with Pneumonia in China

Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

Mechanisms of immunotherapy: a historical perspective

Early safety indicators of COVID-19 convalescent plasma in 5,000 patients

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Treatment of 5 Critically Ill Patients With

With Convalescent Plasma

Integrated Management of Adolescent and Adult Illness (IMAI) District Clinician Manual: Hospital Care for Adolescents and Adults. GUIDELINES FOR THE MANAGEMENT OF COMMON ILLNESSES WITH LIMITED RESOURCES

Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease

R&D Blueprint and COVID-19. World Health Organization

American Association of Blood Banks (AABB)

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol

Challenges of convalescent plasma infusion therapy in

Middle East respiratory coronavirus infection: a single centre experience

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta -analysis

This work was supported by Ministry Of Health in Kuwait. We thank Jeethu Anu Geo and Jibi Roshan for the technical support and reviewing the data, Kuwait University. We also thank Dr Mohammed Buhamra, for the technical support from the COVID-19 dispatch team,Ministry Of Health, Kuwait.J o u r n a l P r e -p r o o f